Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
80 hedge funds and large institutions have $89.7M invested in Catalyst Pharmaceutical in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
16% more funds holding
Funds holding: 69 → 80 (+11)
1.59% more ownership
Funds ownership: 40.51% → 42.11% (+1.6%)
4% less capital invested
Capital invested by funds: $93.7M → $89.7M (-$4.01M)
36% less call options, than puts
Call options by funds: $83K | Put options by funds: $130K
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.28M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.31M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$1.01M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$967K |
| 5 |
Morgan Stanley
New York
|
+$730K |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$1.25M |
| 2 |
Renaissance Technologies
New York
|
-$851K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$851K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$566K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$190K |
CPRX Hedge Fund Activity: Q3 2017 in Review
80 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2017, worth a combined $89.7M — down 4.3% from $93.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CPRX positions and 3 closed out — a net gain of 12 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.28M. The largest seller was Broadfin Capital, cutting an estimated $1.25M.
- 80 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2017, up from 69 in Q2 2017.
- Funds reported $89.7M of Catalyst Pharmaceutical stock for Q3 2017, down 4.3% quarter-over-quarter.
- 15 funds opened new Catalyst Pharmaceutical positions in Q3 2017 and 3 closed out, a net change of +12 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2017 was Avoro Capital Advisors, an estimated $2.28M added.
- The largest Catalyst Pharmaceutical seller in Q3 2017 was Broadfin Capital, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2017.